Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

KEYNOTE-040 investigators

Research output: Contribution to journal › Article › peer-review

994 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences